News

People with Cushing’s disease often do an unusual amount of eating at night — but this behavior is driven mainly by mental health challenges and sleep disturbances, not because of the hormonal imbalance that underlies the disease. That’s according to a study, “Night…

Asedebart, an experimental treatment designed to ease symptoms in Cushing’s disease and other forms of endogenous Cushing’s syndrome, has been granted orphan drug status in the European Union. That designation, awarded to the Lundbeck therapy by the European Commission, aims to incentivize the development of treatments for rare…

People with Cushing’s syndrome may continue to have excess abdominal fat and diabetes years after achieving disease remission, putting them at an increased risk of experiencing cardiovascular, or heart-related, problems, a new study from Europe found. The data showed that, seven years after remission, individuals who’d had Cushing’s were more…

An exceptionally small pituitary tumor caused severe Cushing’s disease in a young man, leading doctors to take an unusual treatment approach after determining the disease-causing microadenoma would be too difficult to remove surgically, according to a case report from Iraq. Instead of surgery — the standard treatment for…

People with Cushing’s syndrome may experience lasting fatigue, reduced work ability, and disability years after treatment, including during remission, a new study shows. Researchers found that people with both active Cushing’s and disease in remission reported poor work ability. Among those in remission, fatigue and disability were also common, showing…

Serious infections requiring hospitalization remain a long-term concern in Cushing’s syndrome, even after the disease goes into remission, according to a real-world study that followed more than 600 patients for about 13 years. Researchers found that adults with Cushing’s syndrome were more than twice as likely as matched people without…

Corcept Therapeutics has resubmitted its application to the U.S. Food and Drug Administration (FDA) seeking approval of relacorilant to treat endogenous Cushing’s syndrome, with new analyses as requested by the agency. The company submitted its initial new drug…